Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib for recurrent or persistent rare gynecologic malignancies with homologous recombination deficiency
jRCT2031210264Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of niraparib in uterine leiomyosarcoma (uLMS), endometrial cancer (EC), uterine sarcoma and 3 more (3 cohorts), sponsored by Takeda. Primary endpoints: Overall response rate in Cohort A, Overall response rate in Cohort B and 1 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
uterine leiomyosarcoma (uLMS)endometrial cancer (EC)uterine sarcomaCervical Cancer (CC)Vulval carcinoma
Beyond the preview
Go deeper on jRCT2031210264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210264.